Welcome to our dedicated page for Spyre Therapeutics news (Ticker: SYRE), a resource for investors and traders seeking the latest updates and insights on Spyre Therapeutics stock.
Spyre Therapeutics develops long-acting antibody therapies and antibody combinations for inflammatory bowel disease and rheumatic diseases. The company’s pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A and IL-23, with programs such as SPY001, SPY002 and SPY003 evaluated as monotherapies and pairwise combinations.
Recurring news for Spyre Therapeutics includes clinical updates from the SKYLINE platform trial in ulcerative colitis and the SKYWAY basket trial in rheumatic diseases, financial results and corporate updates, common-stock financing activity, and equity inducement awards under its 2018 Equity Inducement Plan. Company announcements also describe balance-sheet actions, development priorities and data presentations tied to its immune-mediated disease pipeline.
Spyre Therapeutics (NASDAQ: SYRE) granted stock options to purchase an aggregate of 51,300 shares of common stock to four non-executive employees as equity inducement awards under its 2018 Equity Inducement Plan.
The options have a 10-year term, a $70.54 exercise price, and a time-based vesting schedule tied to continued service.
Spyre Therapeutics (NASDAQ: SYRE) completed enrollment for all sub-studies in the SKYWAY Phase 2 basket trial of SPY072 (anti-TL1A) in rheumatic diseases, including RA, PsA, and axSpA.
The company reiterates Phase 2 efficacy readouts in Q3–Q4 2026 and is presenting supportive preclinical data at EULAR 2026.
Spyre Therapeutics (NASDAQ: SYRE) will participate in two June 2026 healthcare investor conferences. Management joins the Jefferies Global Healthcare Conference in New York on June 3, 2026 at 12:15 pm ET and the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 8, 2026 at 10:00 am ET. Live audio webcasts, replays, and one-on-one investor meetings are planned.
Spyre Therapeutics (NASDAQ:SYRE) reported Q1 2026 results and program updates on May 5, 2026. Key highlights: SPY001 Part A topline induction data showed RHI reduction of 9.2 points (p<0.0001), clinical remission 40%, endoscopic improvement 51%. Company accelerated RA sub-study topline to Q3 2026 and remains on track for six Phase 2 readouts in 2026. Financials: raised $463M gross; pro forma cash of $1.1768B as of March 31, 2026, with expected runway into H2 2029. Q1 net loss was $69.0M.
Spyre Therapeutics (NASDAQ: SYRE) announced inducement stock-option grants to four non-executive employees totaling 20,800 options, approved May 1, 2026 under the 2018 Equity Inducement Plan.
The options carry a 10-year term, an exercise price of $69.42 (Nasdaq close May 1, 2026) and a standard 1/4 then monthly vesting schedule.
Spyre Therapeutics (Nasdaq: SYRE) closed an underwritten public offering on April 16, 2026, selling 7,475,000 shares at $62.00 per share, including full exercise of a 975,000‑share overallotment option. Gross proceeds were approximately $463.5 million before underwriting discounts and offering expenses.
Jefferies, Goldman Sachs, Evercore ISI and Guggenheim acted as joint book‑running managers; a final prospectus supplement was filed April 14, 2026 and related filings became effective February 27, 2026.
Spyre Therapeutics (Nasdaq: SYRE) priced an upsized underwritten offering of 6,500,000 common shares at $62.00 per share, raising approximately $403.0 million gross before fees.
The company granted underwriters a 30-day option to purchase up to an additional ~$60.5 million of shares; closing is expected on or about April 16, 2026, subject to customary conditions.
Spyre Therapeutics (Nasdaq: SYRE) announced a proposed underwritten public offering of $300.0 million of common stock, with a 30-day underwriter option to purchase an additional $45.0 million.
All shares will be sold by Spyre; the offering is subject to market conditions and a final prospectus supplement will set the offering terms. A Form S-3 registration statement is effective.
Spyre (NASDAQ: SYRE) reported 12-week Part A induction results from the Phase 2 SKYLINE trial for SPY001 in moderate-to-severe ulcerative colitis. SPY001 met the primary endpoint with a -9.2 point RHI change (p<0.0001) at Week 12.
Key secondary results: clinical remission 40%, endoscopic improvement 51%, change in modified Mayo score -3.7. Safety was described as consistent with the α4β7 class; one SAE (2%) deemed not drug-related. Part A recruitment closed; Part B enrollment is open with monotherapy and combination cohorts, and additional Part A readouts expected mid-2026 to Q3 2026.
Spyre Therapeutics (NASDAQ: SYRE) will report SPY001 Part A induction topline results from the SKYLINE trial in moderate-to-severe ulcerative colitis on Monday, April 13, 2026.
The company will host a conference call and webcast at 8:00am ET on April 13, 2026 to discuss the results; archived access will be available via Spyre's Investor Relations site.